Outlook Therapeutics (OTLK) Short term Debt (2015 - 2026)

Outlook Therapeutics (OTLK) reported Short term Debt of $6.0 million for Q1 2026, down 10.43% quarter-over-quarter from $6.7 million in Q3 2019.

Outlook Therapeutics (OTLK) Short term Debt (2015 - 2026) Analysis & Trends

Outlook Therapeutics (OTLK) has 6 years of Short term Debt data on file, last reported at $6.0 million in Q1 2026.

Short term Debt for Q1 2026 came in at $6.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (changed N/A YoY), and the FY2019 annual result was $6.7 million, up 9976.71% from the prior year.
Short term Debt declined to $6.0 million in Q1 2026 per OTLK's latest filing, from $6.7 million in the prior quarter.
Over five years, Short term Debt peaked at $6.0 million in Q1 2026 and troughed at $6.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Outlook Therapeutics	51.13 Mn	43.39 Mn	-21,888.00

Download Data